根据增资协议及股权转让协议，海松资本同意支付给北京加科思人民币1.25亿元的现金作为首付款，以 及人民币7500万元作为第二期里程碑付款收购加科瑞康80%的股权。于交易完成后，加科瑞康将由北京 加科思拥有10%、海松资本拥有80%，产业合作方拥有10%股权。 智通财经APP获悉，加科思-B(01167)高开近3%，截至发稿，涨2.43%，报8港元，成交额47.04万港元。 消息面上，加科思-B发布公告，(一)北京加科思新药研发有限公司(北京加科思)、北京加科瑞康医药科 技有限公司(加科瑞康)与一名产业合作方近期签订了增资协议；及(二)北京加科思、加科瑞康、山西海 松管理咨询合伙企业(有限合伙)(海松资本)及产业合作方近期订立了股权转让协议。 截至本公告日期，北京加科思持有加科瑞康100%的权益，而北京加科思为公司间接控股附属公司。加 科瑞康主要业务为内部研发心血管疾病治疗药物，并且拥有本次交易的早期心血管研究开发项目相关的 知识产权。 ...

Core Viewpoint - The company is focusing on its long-term strategic direction of oncology innovation by divesting non-oncology assets, which will optimize resource allocation and enhance organizational efficiency [1][3]. Group 1: Investment and Strategic Moves - The company announced a capital increase and equity transfer agreement where Haisheng Capital will acquire 80% of its subsidiary, Beijing Jike Ruikang Pharmaceutical Technology Co., Ltd., for RMB 200 million [1]. - After the transaction, the ownership structure will be 10% for the company, 80% for Haisheng Capital, and 10% for an industry partner [1]. - The divestment aligns with the company's strategy to focus on its oncology pipeline, particularly in KRAS and iADC directions [1][3]. Group 2: Product Development and Clinical Trials - The company's KRAS G12C inhibitor, Glecirasib, has been approved for second-line treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC) in China, marking a significant commercial breakthrough [2]. - Glecirasib is partnered with Elysium, which paid RMB 200 million upfront and an additional RMB 50 million milestone payment this year [2]. - The company is conducting registration trials for Glecirasib in combination with SHP2 inhibitor JAB-3312 for first-line treatment of KRAS G12C mutated NSCLC [2]. Group 3: Future Prospects and Market Position - The company is advancing its second-generation product, EGFR-KRAS G12D tADC, expected to submit an IND application in the second half of 2026 [3]. - Market analysts believe the company's pipeline value and long-term growth potential are not fully reflected in its current stock price, with a market cap comparison indicating significant undervaluation [3]. - The chairman and associated parties have significantly increased their holdings, signaling strong confidence in the company's long-term development [3].

根据增资协议及股权转让协议，海松资本同意支付给北京加科思人民币1.25亿元的现金作为首付款，以 及人民币7500万元作为第二期里程碑付款收购加科瑞康80%的股权。于交易完成后，加科瑞康将由北京 加科思拥有10%、海松资本拥有80%，产业合作方拥有10%股权。 截至本公告日期，北京加科思持有加科瑞康100%的权益，而北京加科思为公司间接控股附属公司。加 科瑞康主要业务为内部研发心血管疾病治疗药物，并且拥有本次交易的早期心血管研究开发项目相关的 知识产权。 消息面上，加科思-B发布公告，(一)北京加科思新药研发有限公司(北京加科思)、北京加科瑞康医药 （002589）科技有限公司(加科瑞康)与一名产业合作方近期签订了增资协议；及(二)北京加科思、加科 瑞康、山西海松管理咨询合伙企业(有限合伙)(海松资本)及产业合作方近期订立了股权转让协议。 加科思-B(01167)高开近3%，截至发稿，涨2.43%，报8港元，成交额47.04万港元。 ...

Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Group 1 - The core point of the news is that 加科思-B (01167.HK) has entered into a capital increase agreement and a share transfer agreement with a strategic partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - 海松资本 will pay RMB 1.25 billion as an initial payment and RMB 750 million as a milestone payment for the acquisition [1] - After the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the strategic partner will hold 10% [1] Group 2 - 加科瑞康 is focused on the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research projects [1] - The transaction aligns with the company's strategic focus on developing innovative oncology products and solutions, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2]

Group 1 - The company announced a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of the shares in a subsidiary focused on cardiovascular drug development [1][2] - After the completion of the transaction, the ownership structure will be: Beijing Jakesi will hold 10%, Haisong Capital will hold 80%, and the industry partner will hold 10% of the shares in the subsidiary [1] - The subsidiary, Jakesi Ruikang, is primarily engaged in the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research and development projects [1] Group 2 - The company is focused on developing innovative oncology products and solutions to improve health outcomes, aligning with its strategic development in key cancer pipeline products [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2] - The transaction aims to optimize capital allocation and enhance organizational efficiency while maintaining future value through a risk-sharing model [2]

Group 1 - The company, 加科思-B, has signed a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - After the completion of the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the industry partner will hold 10% [1] - 加科瑞康 focuses on the internal research and development of cardiovascular disease treatment drugs and holds relevant intellectual property for early-stage cardiovascular research and development projects [1] Group 2 - The company is committed to developing innovative oncology products and solutions to improve health outcomes [2] - The transaction aligns with the company's strategic focus on key oncology pipeline products targeting various critical cellular pathways, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 訂立增資協議及股權轉讓協議 本公司致力於開發及提供新的創新腫瘤產品及解決方案，以改善人們的健康狀況。加科 瑞康為本集團一個早期心血管研究與開發項目的項目公司。該交易符合本集團聚焦不同 關鍵細胞通路的腫瘤方向關鍵管線產品（包括KRAS、MYC、P53及腫瘤免疫等）的戰略發 展，優化資本配置，全力保障腫瘤治療核心管線的開發，實現戰略聚焦，提升組織效率， 同時以風險共擔模式保留專案未來價值。股權轉讓對價（扣除各項稅款及費用後）擬用於 本公司的Pan-KRAS抑制劑以及其他創新腫瘤項目的研發、生產及商業化。 考慮到上述因素，本公司董事（「董事」）（包括獨立非執行董事）認為增資協議及股權轉讓 協 ...

香港联交所最新资料显示，10月14日，加科思-B(01167)股东将股票由香港上海汇丰银行转入中信里昂 证券，转仓市值3.14亿港元，占比5.04%。 加科思发布2025年中期业绩，该集团期内取得4566.4万元人民币，去年同期为零收入;公司拥有人应占 亏损5899.4万元，同比收窄65.1%。公告称，收入增长主要得益于艾力斯许可协议的里程碑付款。 ...

加科思发布2025年中期业绩，该集团期内取得4566.4万元人民币，去年同期为零收入;公司拥有人应占 亏损5899.4万元，同比收窄65.1%。公告称，收入增长主要得益于艾力斯许可协议的里程碑付款。 智通财经APP获悉，香港联交所最新资料显示，10月14日，加科思-B(01167)股东将股票由香港上海汇丰 银行转入中信里昂证券，转仓市值3.14亿港元，占比5.04%。 ...